Cresanto Global (531207)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• ROE is positive at 5.16%, though the base is tiny
• Piotroski F-Score of 5/9 suggests some financial health metrics are in decent shape
• Reported profit growth of 64% shows some improvement, even if from a very low base
• The extremely small market cap leaves room for a true operational revival, if one ever happens

Concerns

• Latest quarterly sales are ₹0 Cr and net profit is ₹-0 Cr, indicating no active operating business
• Price of ₹2.50 is below the 52-week range of ₹3.48–₹4.65, reflecting persistent weakness
• P/E of 0.00 and ROCE of 0.00 mean no meaningful earnings or return on capital
• Book value, debt/equity, and promoter holding are unavailable, leaving investors blind on solvency and ownership

AI Analysis

At ₹2.50, Cresanto Global has a market cap of just ₹2 crore. That alone tells me this is a microcap at the edge of investability. Graham would insist on figures; here the figures are almost absent. Book value is not available, debt/equity is not available, promoter holding is not available. Sales for the latest quarter are ₹0 crore, and net profit is ₹-0 crore. A company with no revenue cannot be analyzed as a going concern; it is an option, not a business. The P/E of 0.00 is not cheapness—it is a sign of no meaningful earnings. ROCE is 0.00, confirming capital is producing no return. ROE of 5.16% is positive but meaningless on a tiny equity base. Piotroski F-Score of 5/9 is mediocre, not a green light. Profit growth of 64% looks impressive but with sales growth of 0%, it is likely a base effect or cost cutting, not a repeatable engine. The price is actually below the 52-week range of ₹3.48–₹4.65, which shows weakness and almost no trading in a thin market. There is no dividend, no moat I can identify, and no data to measure competitive position. In pharma, a credible business needs R&D spending, product approvals, and revenue visibility; none of that is visible here. I would not buy a rumor. If the company someday reports real sales, real margins, and a clean balance sheet, I would revisit. Until then, this is a pass. In the words of Graham: 'The investor's chief problem—and even his worst enemy—is likely to be himself.' The temptation to speculate in a ₹2 crore shell is exactly the kind of mistake I avoid.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer